9 METERS BIOPHARMA, INC.
DelistedCIK 1551986fmd_0T321BR2NF8Z83H9N70Z3WR0B3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Mar 31, 2023, 32 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 8 | 3 | 2 | – | – | – | – | – |
| Gross profit | 0 | 1 | (0) | – | – | – | – | – |
| Research and development | 0 | 0 | 4 | 8 | 14 | 11 | 22 | 31 |
| Selling, general and administrative | 7 | 6 | 6 | – | – | – | – | – |
| Total operating expenses | 7 | 7 | 11 | 18 | 26 | 61 | 37 | 42 |
| Operating income | (6) | (6) | 11 | 18 | (26) | (61) | (37) | (42) |
| Interest expense | 1 | 1 | 0 | 6 | 2 | 4 | 0 | 3 |
| Interest and investment income | – | – | – | – | – | – | 0 | 1 |
| Other non-operating income (expense) | – | (0) | (0) | (6) | (2) | (1) | (0) | (2) |
| Income before taxes | (9) | (6) | (12) | (24) | (27) | (61) | (37) | (44) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (9) | (6) | (12) | (24) | (27) | (61) | (37) | (44) |
| Net income | (9) | (6) | (12) | (24) | (27) | (61) | (37) | (44) |
| Net income to common shareholders | – | (6) | (9) | – | – | – | – | – |